Foster Pressurised Inhalation Solution 100mcg6mcg per Actuation Singapur - inglise - HSA (Health Sciences Authority)

foster pressurised inhalation solution 100mcg6mcg per actuation

orient europharma pte ltd - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - aerosol, metered - 0.100mg/ actuation - beclometasone dipropionate anhydrous 0.100mg/ actuation; formoterol fumarate dihydrate 0.006mg/actuation

FLUTIFORM® PRESSURISED INHALATION SUSPENSION 125 MICROGRAM5 MICROGRAM PER ACTUATION Singapur - inglise - HSA (Health Sciences Authority)

flutiform® pressurised inhalation suspension 125 microgram5 microgram per actuation

mundipharma pharmaceuticals pte. ltd. - fluticasone propionate; formoterol fumarate dihydrate - aerosol, metered - 125 mcg/actuation - fluticasone propionate 125 mcg/actuation; formoterol fumarate dihydrate 5 mcg/actuation

FLUTIFORM® PRESSURISED INHALATION SUSPENSION 250 MICROGRAM10 MICROGRAM PER ACTUATION Singapur - inglise - HSA (Health Sciences Authority)

flutiform® pressurised inhalation suspension 250 microgram10 microgram per actuation

mundipharma pharmaceuticals pte. ltd. - fluticasone propionate; formoterol fumarate dihydrate - aerosol, metered - 250 mcg/actuation - fluticasone propionate 250 mcg/actuation; formoterol fumarate dihydrate 10 mcg/actuation

Cofsed Linctus Malta - inglise - Medicines Authority

cofsed linctus

thornton & ross limited linthwaite laboratories, huddersfield, hd7 5qh, united kingdom - chlorphenamine maleate, pholcodine, ephedrine hydrochloride - oral suspension - chlorphenamine maleate 2 mg/5ml pholcodine 5 mg/5ml ephedrine hydrochloride 8 mg/5ml - cough and cold preparations

MEDISIP WITH DECONGESTANT POWDER FOR ORAL SOLUTION 500/12.2 Milligram Powder for Oral Solution Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

medisip with decongestant powder for oral solution 500/12.2 milligram powder for oral solution

actavis group ptc ehf - paracetamol, phenylephrine hydrochloride - powder for oral solution - 500/12.2 milligram - analgesics and antipyretics

Rowasip Cold and Flu with Decongestant 500 mg/12.2 mg powder for oral solution Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

rowasip cold and flu with decongestant 500 mg/12.2 mg powder for oral solution

rowex ltd - paracetamol; phenylephrine hydrochloride - powder for oral solution - 500 mg/12.2 milligram(s) - anilides; paracetamol, combinations excl. psycholeptics

Rowasip Max Strength Cold and Flu with Decongestant 1000 mg/12.2 mg powder for oral solution Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

rowasip max strength cold and flu with decongestant 1000 mg/12.2 mg powder for oral solution

rowex ltd - phenylephrine hydrochloride; paracetamol - powder for oral solution - 1000 mg/12.2 milligram(s) - anilides; paracetamol, combinations excl. psycholeptics

BiResp Spiromax Euroopa Liit - inglise - EMA (European Medicines Agency)

biresp spiromax

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists.copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁)

DuoResp Spiromax Euroopa Liit - inglise - EMA (European Medicines Agency)

duoresp spiromax

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists.copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁)

Trimbow Euroopa Liit - inglise - EMA (European Medicines Agency)

trimbow

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.